NO20064766L - 2-fenylpropionsyrederivater og farmasoytiske preparater som inneholder dem - Google Patents
2-fenylpropionsyrederivater og farmasoytiske preparater som inneholder demInfo
- Publication number
- NO20064766L NO20064766L NO20064766A NO20064766A NO20064766L NO 20064766 L NO20064766 L NO 20064766L NO 20064766 A NO20064766 A NO 20064766A NO 20064766 A NO20064766 A NO 20064766A NO 20064766 L NO20064766 L NO 20064766L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- acid derivatives
- prevention
- compounds
- pharmaceutical compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical class OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 title 1
- 102000004890 Interleukin-8 Human genes 0.000 abstract 2
- 108090001007 Interleukin-8 Proteins 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 abstract 2
- 229940096397 interleukin-8 Drugs 0.000 abstract 2
- 210000000440 neutrophil Anatomy 0.000 abstract 2
- 230000007170 pathology Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 abstract 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 abstract 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 abstract 1
- 206010034277 Pemphigoid Diseases 0.000 abstract 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 abstract 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 abstract 1
- 208000000594 bullous pemphigoid Diseases 0.000 abstract 1
- 230000003399 chemotactic effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 150000005599 propionic acid derivatives Chemical class 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
4-(trifluormetansulfonyloksyfenyl)propionsyrederivater og farmasøytiske preparater som inneholder slike forbindelser er anvendbare for inhibering av den kjemotaktiske aktivering av nøytrofile celler (PMN- leukocytter) som induseres ved interaksjonen mellom interleukin-8 (IL-8) og membranreseptorene CXCRl og CXCR2. Forbindelsene anvendes for forebyggelse og behandling av sykdomstilstander som skyldes slik aktivering. Det er å merke seg at disse metabolittene mangler syklooksygenaseinhiberende aktivitet og er spesielt anvendbare for behandling av sykdomstilstander som avhenger av nøyfrofile celler, feks. psoriasis, ulcerøs kolitt, melanom, kronisk obstruktiv lungesykdom (KOLS), bulløs pemfigoid, reumatoid artritt, idiopatisk fibrose og glomerulonefiitt, og for forebyggelse og behandling av skader grunnet ischemi og reperfiisjon.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04101202 | 2004-03-23 | ||
| PCT/EP2005/051302 WO2005090295A2 (en) | 2004-03-23 | 2005-03-21 | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20064766L true NO20064766L (no) | 2006-10-20 |
| NO337685B1 NO337685B1 (no) | 2016-06-06 |
Family
ID=34970877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20064766A NO337685B1 (no) | 2004-03-23 | 2006-10-20 | 2-fenylpropionsyrederivater og farmasøytiske preparater som inneholder dem |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8039656B2 (no) |
| EP (1) | EP1776336B1 (no) |
| JP (1) | JP4871257B2 (no) |
| CN (2) | CN1934077B (no) |
| AT (1) | ATE444286T1 (no) |
| AU (1) | AU2005223402B2 (no) |
| CA (1) | CA2553705C (no) |
| CY (1) | CY1109687T1 (no) |
| DE (1) | DE602005016937D1 (no) |
| DK (1) | DK1776336T3 (no) |
| ES (1) | ES2333445T3 (no) |
| HR (1) | HRP20090681T1 (no) |
| ME (1) | ME01763B (no) |
| NO (1) | NO337685B1 (no) |
| PL (1) | PL1776336T3 (no) |
| PT (1) | PT1776336E (no) |
| RS (1) | RS51109B (no) |
| RU (1) | RU2375347C2 (no) |
| SI (1) | SI1776336T1 (no) |
| WO (1) | WO2005090295A2 (no) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2458051C2 (ru) * | 2005-11-24 | 2012-08-10 | ДОМПЕ ФА.Р.МА С.п.А. | (r)-арилалкиламинопроизводные и содержащие их фармацевтические композиции |
| HRP20130989T1 (hr) * | 2006-05-18 | 2013-12-06 | Dompe` S.P.A. | (2r) -2-[(4-sulfonil)aminofenil] propanamidi i farmaceutski sastavi koji ih sadrže |
| PT2094638E (pt) | 2006-12-19 | 2012-11-20 | Dompe Spa | Ácidos 2-aril-fluoropropanóicos e derivados e composições farmacêuticas que os contêm |
| EP2166006A1 (en) * | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| EP2308485A1 (en) | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Sulfonamides for the prevention of diabetes |
| EP2308484A1 (en) * | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets |
| EP2316820A1 (en) * | 2009-10-28 | 2011-05-04 | Dompe S.p.A. | 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them |
| MD480Z (ro) * | 2011-07-07 | 2012-09-30 | Elvira Andon | Metoda de tratament al colitei ulceroase nespecifice acute |
| CN103159649B (zh) * | 2011-12-19 | 2016-03-09 | 天津市国际生物医药联合研究院 | 磺酰胺类化合物的制备及其应用 |
| CN103159650B (zh) * | 2011-12-19 | 2016-04-20 | 天津市国际生物医药联合研究院 | 芳香杂环磺酰胺类化合物的制备及其应用 |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| US10561676B2 (en) * | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| EP3117835A1 (en) * | 2015-07-14 | 2017-01-18 | Dompé farmaceutici s.p.a. | Il-8 inhibitors for use in the treatment of certain urological disorders |
| EP3192504A1 (en) | 2016-01-15 | 2017-07-19 | Dompé farmaceutici S.p.A. | Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy |
| ES2893701T3 (es) | 2016-01-15 | 2022-02-09 | Dompe Farm Spa | Inhibidores de IL-8 para su uso en el tratamiento de neuropatía periférica inducida por quimioterapia |
| CN117503933A (zh) | 2016-10-03 | 2024-02-06 | 儿童医疗中心公司 | 糖尿病肾病的预防和治疗 |
| EP3342407A1 (en) | 2017-01-03 | 2018-07-04 | Dompé farmaceutici S.p.A. | Il-8 inihibitors for use in the treatment of some urological disorders |
| EP3409277A1 (en) * | 2017-05-30 | 2018-12-05 | Dompé farmaceutici s.p.a. | Il-8 inhibitors for use in the treatment and/or prevention of bacterial secondary infections |
| EP3476390A1 (en) * | 2017-10-24 | 2019-05-01 | Dompé farmaceutici S.p.A. | Il-8 inhibitors for use in the treatment of sarcomas |
| EP3498269A1 (en) * | 2017-12-12 | 2019-06-19 | Dompé farmaceutici S.p.A. | C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain |
| EP3868368A1 (en) | 2020-02-21 | 2021-08-25 | Dompe' Farmaceutici S.P.A. | Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof |
| EP3868369A1 (en) | 2020-02-21 | 2021-08-25 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue |
| EP3884932A1 (en) | 2020-03-26 | 2021-09-29 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitors for use in the treatment of covid-19 |
| EP4125848A1 (en) | 2020-03-26 | 2023-02-08 | Dompe' Farmaceutici SpA | Cxcl8 inhibitors for use in the treatment of covid-19 |
| EP4008325A1 (en) | 2020-12-02 | 2022-06-08 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitors for use in the treatment of covid-19 |
| WO2022098822A1 (en) * | 2020-11-05 | 2022-05-12 | Icahn School Of Medicine At Mount Sinai | Cxcr1/cxcr2 inhibitors for use in treating myelofibrosis |
| EP4052702A1 (en) | 2021-03-04 | 2022-09-07 | Dompé farmaceutici S.p.a. | Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures |
| KR20230092100A (ko) * | 2021-12-16 | 2023-06-26 | 주식회사 동진쎄미켐 | 염 화합물 및 이를 포함하는 산확산 억제제, 포토레지스트 조성물 |
| EP4397305A1 (en) | 2023-01-05 | 2024-07-10 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid |
| EP4563594A1 (en) | 2023-11-28 | 2025-06-04 | Dompe' Farmaceutici SpA | Cxcl8 inhibitors for use in the treatment of tumors with low stromal cav1 levels |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU723895B2 (en) * | 1997-01-29 | 2000-09-07 | Pfizer Inc. | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| IT1303249B1 (it) * | 1998-10-23 | 2000-11-06 | Dompe Spa | Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono. |
| IT1317826B1 (it) * | 2000-02-11 | 2003-07-15 | Dompe Spa | Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8. |
| ITMI20010395A1 (it) | 2001-02-27 | 2002-08-27 | Dompe Spa | Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate |
| ITMI20012025A1 (it) * | 2001-09-28 | 2003-03-28 | Dompe Spa | Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono |
| ITMI20012434A1 (it) * | 2001-11-20 | 2003-05-20 | Dompe Spa | Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono |
| EP1590314B1 (en) * | 2003-02-06 | 2015-08-05 | Dompé farmaceutici s.p.a. | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them |
| RU2375346C2 (ru) * | 2003-09-25 | 2009-12-10 | ДОМПЕ ФА.Р.МА С.п.А. | Амидины и их производные и содержащие их фармацевтические композиции |
-
2005
- 2005-03-21 PL PL05729779T patent/PL1776336T3/pl unknown
- 2005-03-21 ES ES05729779T patent/ES2333445T3/es not_active Expired - Lifetime
- 2005-03-21 RU RU2006137272/04A patent/RU2375347C2/ru active
- 2005-03-21 RS RSP-2009/0568A patent/RS51109B/sr unknown
- 2005-03-21 HR HR20090681T patent/HRP20090681T1/hr unknown
- 2005-03-21 JP JP2007504413A patent/JP4871257B2/ja not_active Expired - Lifetime
- 2005-03-21 AU AU2005223402A patent/AU2005223402B2/en not_active Expired
- 2005-03-21 SI SI200530869T patent/SI1776336T1/sl unknown
- 2005-03-21 PT PT05729779T patent/PT1776336E/pt unknown
- 2005-03-21 CN CN200580008890XA patent/CN1934077B/zh not_active Expired - Lifetime
- 2005-03-21 ME MEP-2009-568A patent/ME01763B/me unknown
- 2005-03-21 DK DK05729779.8T patent/DK1776336T3/da active
- 2005-03-21 WO PCT/EP2005/051302 patent/WO2005090295A2/en not_active Ceased
- 2005-03-21 EP EP05729779A patent/EP1776336B1/en not_active Expired - Lifetime
- 2005-03-21 AT AT05729779T patent/ATE444286T1/de active
- 2005-03-21 DE DE602005016937T patent/DE602005016937D1/de not_active Expired - Lifetime
- 2005-03-21 US US10/592,572 patent/US8039656B2/en active Active
- 2005-03-21 CA CA2553705A patent/CA2553705C/en not_active Expired - Lifetime
- 2005-03-21 CN CN2010102609529A patent/CN101912382B/zh not_active Expired - Lifetime
-
2006
- 2006-10-20 NO NO20064766A patent/NO337685B1/no unknown
-
2009
- 2009-12-18 CY CY20091101318T patent/CY1109687T1/el unknown
-
2011
- 2011-09-15 US US13/234,125 patent/US8293788B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20064766L (no) | 2-fenylpropionsyrederivater og farmasoytiske preparater som inneholder dem | |
| WO2004080951A3 (en) | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | |
| Cocco et al. | Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties | |
| NO20074641L (no) | 1-Acetic Acid-Indole Derivatives with PGD2 Antagonist Activity | |
| NO20073663L (no) | Tiazol-4-karboksamid-derivater som mGluR5 antagonister | |
| ATE463495T1 (de) | Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten | |
| Gilbert et al. | N-((8-Hydroxy-5-substituted-quinolin-7-yl)(phenyl) methyl)-2-phenyloxy/amino-acetamide inhibitors of ADAMTS-5 (Aggrecanase-2) | |
| George et al. | Discovery of thieno [2, 3-c] pyridines as potent COT inhibitors | |
| BR0214322A (pt) | ácidos 2-aril-propiÈnicos e composições farmacêuticas contendo os mesmos | |
| NO20080165L (no) | Alfa-(aryl-OR heteroaryl-metyl)-beta piperidinopropanamidforbindelser som ORL1-receptorantagonister | |
| NO20054017L (no) | 2-aryl-eddiksyrer, deres derivater og farmasoytisk sammensetninger som inneholder dem | |
| Das et al. | Discovery and SAR of 2-amino-5-[(thiomethyl) aryl] thiazoles as potent and selective Itk inhibitors | |
| Miller et al. | Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureas—the effect of capping the distal basic piperidine nitrogen | |
| DE602006007210D1 (de) | Metaboliten aus 2-arylpropionsäure-derivaten und pharmazeutische zusammensetzungen damit | |
| HRP20090489T1 (hr) | Hidantoinski derivati korisni kao inhibitori metaloproteinaza | |
| Yokokawa et al. | Recent advances in the discovery of non-peptidic direct renin inhibitors as antihypertensives: new patent applications in years 2000–2008 | |
| Wei et al. | CCR5 receptor antagonists: Discovery and SAR study of guanylhydrazone derivatives | |
| De Savi et al. | Selective non zinc binding inhibitors of MMP13 | |
| NO20055752L (no) | N-ureidoalkyl-piperidiner som modulerer forbindelser av kjemokinreseptor-aktivitet | |
| NO20080285L (no) | Alfa-(aryl- eller heteroarylmetyl)-beta-piperidinopropionsyreforbindelser som ORL-1-reseptorantagonist | |
| NO20061721L (no) | Amidiner og derivater derav og farmasoytiske sammensetninger som inneholder disse | |
| Sutton et al. | From virtual to clinical: the discovery of PGN-1531, a novel antagonist of the prostanoid EP4 receptor | |
| Miller et al. | Synthesis and SAR of N-(4-(4-alklylpiperazin-1-yl) phenyl) benzamides as muscarinic acetylcholine receptor subtype 1 (M1) anatgonists | |
| NO20081131L (no) | Stabilisert protease sammensetning | |
| Wu et al. | Design and synthesis of aminophenol-Based factor xa inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: DOMPE FARMACEUTICI S.P.A., IT |